133 related articles for article (PubMed ID: 15288254)
21. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenesis agents in the treatment of soft tissue sarcomas.
Ganjoo K; Jacobs C
Cancer; 2010 Mar; 116(5):1177-83. PubMed ID: 20052715
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of angiogenesis in cancer patients.
Verheul HM; Pinedo HM
Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
[TBL] [Abstract][Full Text] [Related]
25. Pharmacia's SU5416 not effective.
Expert Rev Anticancer Ther; 2002 Feb; 2(1):5. PubMed ID: 12113066
[No Abstract] [Full Text] [Related]
26. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
27. Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review).
Kanda S; Miyata Y; Kanetake H; Smithgall TE
Int J Mol Med; 2007 Jul; 20(1):113-21. PubMed ID: 17549397
[TBL] [Abstract][Full Text] [Related]
28. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S; Gruninger RH; Fuentes-Pesquera A; Connolly PJ; Seamon JA; Hazel S; Tominovich R; Hollister B; Napier C; D'Andrea MR; Reuman M; Bignan G; Tuman R; Johnson D; Moffatt D; Batchelor M; Foley A; O'Connell J; Allen R; Perry M; Jolliffe L; Middleton SA
Mol Pharmacol; 2004 Sep; 66(3):635-47. PubMed ID: 15322256
[TBL] [Abstract][Full Text] [Related]
29. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
Holash J; Thurston G; Rudge JS; Yancopoulos GD; Adjei AA; Bergers G; Pytowski B; Pegram M; Gordon MS
Cancer Metastasis Rev; 2006 Jun; 25(2):243-52. PubMed ID: 16770536
[No Abstract] [Full Text] [Related]
31. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of angiogenesis-relevant receptor tyrosine kinases by sulindac analogues.
Gourzoulidou E; Carpintero M; Baumhof P; Giannis A; Waldmann H
Chembiochem; 2005 Mar; 6(3):527-31. PubMed ID: 15696596
[No Abstract] [Full Text] [Related]
33. Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases.
Hubbard RD; Bamaung NY; Fidanze SD; Erickson SA; Palazzo F; Wilsbacher JL; Zhang Q; Tucker LA; Hu X; Kovar P; Osterling DJ; Johnson EF; Bouska J; Wang J; Davidsen SK; Bell RL; Sheppard GS
Bioorg Med Chem Lett; 2009 Mar; 19(6):1718-21. PubMed ID: 19217287
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
35. Thyroid cancer molecular signaling pathways and use of targeted therapy.
Kundra P; Burman KD
Endocrinol Metab Clin North Am; 2007 Sep; 36(3):839-53, viii. PubMed ID: 17673131
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of signal transduction protein kinases as targets for cancer therapy.
Mikalsen T; Gerits N; Moens U
Biotechnol Annu Rev; 2006; 12():153-223. PubMed ID: 17045195
[TBL] [Abstract][Full Text] [Related]
37. Growth factor receptors: implications in tumor biology.
Srinivasan DM; Kapoor M; Kojima F; Crofford LJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1246-9. PubMed ID: 16370390
[TBL] [Abstract][Full Text] [Related]
38. [Insulin-like growth factor (IGF)-signalling pathway components are potential therapeutic targets in the treatment of human hepatocellular carcinoma].
Nussbaum T; Samarin J; Schirmacher P; Breuhahn K
Verh Dtsch Ges Pathol; 2007; 91():278-85. PubMed ID: 18314625
[TBL] [Abstract][Full Text] [Related]
39. New antileukemic agents.
Mantadakis E; Kalmanti M
Pediatr Hematol Oncol; 2003; 20(3):173-85. PubMed ID: 12637214
[TBL] [Abstract][Full Text] [Related]
40. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.
García-Echeverría C; Fabbro D
Mini Rev Med Chem; 2004 Mar; 4(3):273-83. PubMed ID: 15032674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]